Boston Scientific Posts Mixed Q3 Earnings, Cuts Annual Guidance

  • Boston Scientific Corp BSX generated net sales of $3.17 billion in Q3 FY22, slightly beating the Wall Street estimate of $3.15 billion.
  • Sales increased 8.1% Y/Y on a reported basis, 13.7% on an operational basis, and 11.5% on an organic basis.
  • The company achieved an adjusted EPS of $0.43, missing the consensus of $0.44.
  • Revenues from MedSurg increased 6.5% to $1.213 billion (9.8% organic), Cardiovascular segment generated $1.958 billion, +9.1% (12.6% organic).
  • The adjusted gross margin remained unchanged at almost 71%, with an adjusted operating income margin of 26%.
  • Outlook: Boston Scientific estimates FY22 sales growth of approximately 6.5% on a reported basis (6.5%-7.5% earlier) and approximately 9% on an organic basis.
  • The company now estimates adjusted EPS of $1.71-$1.74 (prior range of $1.74 - $1.77) compared to the consensus of $1.76.
  • For Q4 FY22, the company forecasts sales growth of 2%-4% on a reported basis and approximately 7%-9% on an organic basis. 
  • It sees adjusted EPS of $0.45-$0.48, compared to the consensus of $0.49.
  • Price Action: BSX shares are up 1.09% at $41.75 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!